GHRP-2

GHRP-2 (Pralmorelin) – Growth Hormone Secretagogue Research Peptide

Synthetic Hexapeptide for Ghrelin Receptor Signaling, Growth Hormone Secretion & Neuroendocrine Research

GHRP-2, also known as Growth Hormone-Releasing Peptide-2 or Pralmorelin, is a synthetic hexapeptide investigated for its ability to stimulate endogenous growth hormone (GH) secretion.

GHRP-2 belongs to the family of growth hormone secretagogues (GHS), a group of compounds that interact with biological pathways regulating pituitary growth hormone release.

Unlike growth hormone-releasing hormone (GHRH) analogues, GHRP-2 primarily acts through the growth hormone secretagogue receptor type 1a (GHS-R1a), the receptor associated with the endogenous hormone ghrelin.

This receptor is involved in the regulation of growth hormone secretion, appetite and several neuroendocrine processes.

Experimental human studies have demonstrated that GHRP-2 can stimulate acute GH secretion. Research has also documented effects on food intake and, under certain experimental conditions, prolactin, adrenocorticotropic hormone (ACTH) and cortisol.

However, an increase in growth hormone secretion does not establish clinically meaningful improvements in muscle growth, fat loss, athletic performance, recovery or longevity.

GHRP-2 has a history of specialized endocrine diagnostic research, but its regulatory status and authorized applications vary by jurisdiction.

ICAME Pharmacy GHRP-2 is intended strictly for laboratory research and development purposes. Not for human or veterinary use.

What Is GHRP-2?

GHRP-2 is a synthetic peptide designed to stimulate the release of growth hormone from the anterior pituitary gland.

It was developed through research on synthetic growth hormone-releasing peptides and their interactions with the hypothalamic–pituitary system.

The compound is structurally distinct from endogenous ghrelin but can activate the same principal receptor, GHS-R1a.

Its biological activity has made it relevant to investigations involving:

• Growth hormone secretion

• Ghrelin receptor pharmacology

• Hypothalamic–pituitary signaling

• GH–IGF-1 axis physiology

• Appetite regulation

• Neuroendocrine responses

• Pituitary function testing

• ACTH and cortisol signaling

• Peptide structure–activity relationships

• Receptor-mediated intracellular signaling

GHRP-2 is not recombinant human growth hormone.

It is a growth hormone secretagogue, meaning it can stimulate the body's own GH-releasing pathways under appropriate experimental conditions.

GHRP-2 Molecular Structure

GHRP-2 is a synthetic hexapeptide consisting of six amino acid residues, including modified residues that contribute to its biological activity.

Amino Acid Sequence

H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂

The sequence contains:

D-Ala — D-Alanine

D-2-Nal — D-2-Naphthylalanine

Ala — Alanine

Trp — Tryptophan

D-Phe — D-Phenylalanine

Lys — Lysine

The peptide also contains a C-terminal amide group.

Molecular Characteristics

Compound Name: Growth Hormone-Releasing Peptide-2

Alternative Name: Pralmorelin

Abbreviation: GHRP-2

Classification: Synthetic Growth Hormone Secretagogue

Peptide Length: 6 Amino Acid Residues

Primary Receptor: GHS-R1a

Principal Research Area: Growth Hormone and Neuroendocrine Physiology

The precise molecular formula and molecular weight of a supplied preparation depend on its chemical form, including the presence of counterions or salts.

For example, a research product described as GHRP-2 acetate should not automatically be assigned the same analytical specifications as the free peptide.

Batch-specific molecular identity and purity should be verified through a Certificate of Analysis.

Discovery and Development of GHRP-2

Growth hormone-releasing peptides were developed through research exploring synthetic compounds capable of stimulating GH secretion.

Early investigations identified peptide structures that influenced pituitary GH release through mechanisms distinct from those of GHRH.

GHRP-2 was developed as a potent synthetic analogue within this research family.

Subsequent studies established its ability to stimulate GH secretion in both experimental animals and humans.

Research later identified the growth hormone secretagogue receptor, providing a molecular framework for understanding the activity of GHRP compounds.

The discovery of ghrelin as an endogenous ligand for this receptor further clarified the relationship between growth hormone secretion, appetite and metabolic signaling.

GHRP-2 remains a useful research compound for examining these interconnected systems.

How Does GHRP-2 Work?

GHRP-2 acts primarily as an agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a).

GHS-R1a is a G protein-coupled receptor expressed in tissues involved in endocrine and metabolic regulation, including the hypothalamus and pituitary gland.

Activation of this receptor can stimulate intracellular signaling associated with GH secretion.

Simplified Mechanism of Action

GHRP-2

↓

GHS-R1a Receptor Activation

↓

Gq/11-Associated Intracellular Signaling

↓

Phospholipase C (PLC) Activation

↓

IP₃ / DAG Signaling and Intracellular Calcium Mobilization

↓

Stimulation of Pituitary GH Secretion

↓

Investigation of Downstream GH–IGF-1 Physiology

This pathway represents a simplified description of established GHS-R1a-associated signaling.

The magnitude of the endocrine response depends on several physiological factors, including pituitary function, metabolic state, age and the experimental setting.

GHRP-2 and the Ghrelin Receptor (GHS-R1a)

Ghrelin is an endogenous peptide hormone associated with growth hormone release, appetite and energy balance.

Its principal signaling receptor is GHS-R1a.

GHRP-2 is structurally different from ghrelin but activates this receptor.

This makes GHRP-2 relevant to research involving:

Ghrelin receptor activation

G protein-coupled receptor signaling

Pituitary hormone secretion

Hypothalamic regulation

Appetite-associated signaling

Endocrine feedback mechanisms

GHRP-2 is commonly described as a ghrelin receptor agonist.

However, its effects should not be assumed to be identical to those of endogenous ghrelin in every tissue or experimental model.

GHRP-2 and Growth Hormone Secretion

Growth hormone is produced and released by specialized cells in the anterior pituitary gland called somatotrophs.

GH secretion is naturally pulsatile and regulated by multiple interacting signals.

Important regulators include:

Growth Hormone-Releasing Hormone (GHRH)

Somatostatin

Ghrelin

Metabolic Signals

Sleep-Associated Physiology

Feedback from GH and IGF-1

GHRP-2 can stimulate GH secretion through GHS-R1a-associated pathways.

Human endocrine studies have documented measurable increases in circulating GH following controlled experimental exposure.

These findings establish GHRP-2 as a biologically active GH secretagogue.

They do not establish that its use produces sustained clinical improvements in body composition, physical performance or health outcomes.

GHRP-2 and the GH–IGF-1 Axis

The growth hormone–insulin-like growth factor-1 (GH–IGF-1) axis plays an important role in growth, metabolism and tissue physiology.

GH is secreted by the pituitary gland.

It acts on multiple tissues, including the liver, where it can stimulate the production of IGF-1.

GH–IGF-1 Signaling Overview

Hypothalamus

↓

Pituitary Regulation

↓

Growth Hormone Release

↓

GH Receptor Activation in Target Tissues

↓

IGF-1-Associated Signaling

↓

Growth and Metabolic Regulation

GHRP-2 influences the upstream regulation of GH secretion.

It does not directly replace GH or IGF-1.

Furthermore, an acute GH response should not be interpreted as proof of sustained IGF-1 elevation or beneficial clinical outcomes.

GHRP-2 and GHRH: Different Signaling Pathways

Growth hormone secretion is regulated by both GHRH and ghrelin-associated pathways.

These systems act through different receptors.

GHRH Signaling

GHRH interacts with the growth hormone-releasing hormone receptor (GHRHR).

This receptor primarily activates Gs-associated signaling.

The resulting pathway involves adenylyl cyclase, cyclic AMP and protein kinase A.

GHRP-2 Signaling

GHRP-2 activates GHS-R1a.

This receptor commonly signals through Gq/11-associated pathways involving phospholipase C and intracellular calcium.

Comparison

The distinction is important when comparing GHRP-2 with GHRH analogues such as sermorelin and CJC-1295.

GHRP-2 and Pituitary Research

The anterior pituitary gland produces several important hormones.

These include:

• Growth hormone

• Prolactin

• Adrenocorticotropic hormone

• Thyroid-stimulating hormone

• Luteinizing hormone

• Follicle-stimulating hormone

GHRP-2 has been investigated primarily for its GH-releasing activity.

However, experimental human studies have also reported effects on prolactin and ACTH-associated endocrine pathways.

This broader activity makes GHRP-2 relevant to research involving pituitary hormone interactions.

It also means that GHRP-2 should not be described as completely selective for GH secretion.

GHRP-2 and Prolactin Research

Prolactin is a pituitary hormone involved in reproductive and metabolic physiology.

Experimental human studies have reported increases in prolactin following GHRP-2 exposure.

These responses have generally been smaller than the principal GH response but remain biologically relevant.

The relationship between GHS-R1a activation and prolactin secretion is complex.

Relevant research topics include:

Pituitary hormone selectivity

Lactotroph signaling

Neuroendocrine interactions

Receptor-mediated endocrine responses

Hormonal feedback

Changes in prolactin are important when interpreting the endocrine profile of GHRP-2.

GHRP-2 and ACTH/Cortisol Research

Adrenocorticotropic hormone (ACTH) is produced by the anterior pituitary gland.

It stimulates the adrenal cortex to produce glucocorticoids, including cortisol.

Human studies have demonstrated that GHRP-2 can influence ACTH and cortisol responses under certain experimental conditions.

HPA Axis Overview

Hypothalamus

↓

Pituitary ACTH Release

↓

Adrenal Cortex

↓

Cortisol Secretion

GHRP-2 has been investigated as a stimulus in research examining hypothalamic–pituitary–adrenal axis function.

However, its ACTH and cortisol responses are not sufficiently specific to make it universally interchangeable with established diagnostic procedures.

In one retrospective clinical study involving 254 patients, the GHRP-2 test showed inadequate diagnostic performance as a replacement for the insulin tolerance test when evaluating adrenal insufficiency.

These findings highlight the importance of distinguishing endocrine stimulation from validated diagnostic accuracy.

GHRP-2 and Appetite Regulation

One of the important biological characteristics of ghrelin receptor signaling is its relationship with appetite.

Because GHRP-2 activates GHS-R1a, researchers have examined whether it influences hunger and food intake.

Controlled human studies have reported increased food intake during experimental GHRP-2 exposure.

In one study involving healthy men, GHRP-2 increased food intake and stimulated GH secretion compared with placebo.

Another study involving lean and obese participants reported dose-dependent increases in food intake.

These observations support the relevance of GHRP-2 to appetite-related research.

However, increased food intake should not be presented as a therapeutic benefit or evidence of healthy weight regulation.

GHRP-2 and Metabolic Research

The GH and ghrelin signaling systems participate in several aspects of metabolism.

These include:

Energy balance

Nutrient-related signaling

Glucose metabolism

Lipid metabolism

Appetite regulation

Endocrine feedback

GHRP-2 has been investigated in experimental studies involving some of these processes.

However, GH secretion and metabolic outcomes are not equivalent.

For example, stimulating GH does not automatically produce clinically meaningful fat loss.

Changes in GH signaling can also affect glucose regulation and insulin sensitivity.

GHRP-2 should therefore not be described as a proven weight-loss or metabolic-health treatment.

GHRP-2 and Skeletal Muscle Research

Growth hormone and IGF-1 are involved in biological pathways relevant to growth and tissue metabolism.

This has generated interest in compounds that stimulate endogenous GH secretion.

GHRP-2 may be relevant to research involving:

• GH receptor biology

• IGF-1-associated signaling

• Muscle metabolism

• Endocrine responses to nutritional state

• Protein turnover

• Growth-associated cellular pathways

However, the available evidence does not establish that GHRP-2 produces clinically meaningful muscle hypertrophy, strength gains or improved athletic performance in healthy humans.

Acute hormone measurements should not be used as substitutes for controlled clinical outcomes.

GHRP-2 and Body Composition Research

Body composition is influenced by multiple factors, including:

Energy intake

Physical activity

Hormonal status

Muscle mass

Adipose tissue metabolism

Age

Genetics

Because GHRP-2 stimulates GH secretion, it has been discussed in relation to body composition research.

However, its demonstrated appetite-stimulating activity may complicate assumptions about energy balance.

There is insufficient high-quality clinical evidence to establish GHRP-2 as an effective intervention for fat loss, muscle gain or body recomposition.

GHRP-2 and Aging-Related Endocrine Physiology

Growth hormone secretion changes across the lifespan.

Age-related changes in GH secretion have been studied in relation to sleep, metabolism and body composition.

GHRP-2 has been investigated in human endocrine research involving different age groups.

Some studies have examined how aging influences the GH response to growth hormone secretagogues.

However, age-associated changes in GH secretion do not establish that increasing GH improves health or extends lifespan.

GHRP-2 is not a clinically validated anti-aging or longevity compound.

GHRP-2 and Sleep-Associated GH Physiology

Growth hormone secretion is associated with sleep physiology.

In many individuals, a prominent GH secretory pulse occurs during early sleep and is related to slow-wave sleep.

This relationship has generated interest in the interaction between sleep-associated neural pathways and GH secretion.

GHRP-2 may be relevant to research examining:

Pulsatile GH secretion

Hypothalamic regulation

Neuroendocrine rhythms

Sleep-associated hormone release

GH secretagogue receptor biology

However, there is insufficient evidence to establish GHRP-2 as an effective treatment for insomnia or as a reliable method for improving sleep quality.

GHRP-2 and Receptor Signaling Research

GHS-R1a is a G protein-coupled receptor.

GPCRs are important molecular targets in pharmacology because they regulate numerous cellular signaling pathways.

GHRP-2 has been used to investigate receptor-associated responses, including:

Receptor activation

Intracellular calcium signaling

Phospholipase C activity

G protein signaling

Receptor pharmacology

Endocrine secretion

The receptor also exhibits complex regulatory behavior, including constitutive activity and interactions with other signaling systems.

These characteristics make GHS-R1a relevant to experimental pharmacology beyond GH secretion alone.

GHRP-2 and Structure–Activity Relationships

Structure–activity relationship (SAR) research examines how changes in molecular structure influence biological activity.

GHRP-2 contains modified amino acid residues, including D-amino acids and a naphthylalanine derivative.

These modifications distinguish it from naturally occurring linear peptides.

Researchers have investigated how such structural characteristics influence:

Receptor affinity

Biological potency

Peptide stability

Receptor selectivity

Endocrine responses

Metabolic degradation

GHRP-2 therefore provides a useful model for studying synthetic peptide design and ghrelin receptor pharmacology.

GHRP-2 vs. GHRP-6

GHRP-2 and GHRP-6 belong to the same family of synthetic GH-releasing peptides.

Both interact with GHS-R1a-associated pathways.

However, their molecular structures and experimental pharmacological profiles differ.

Direct comparisons depend on the experimental protocol and measured endpoints.

Neither compound should be marketed as a clinically validated bodybuilding or anti-aging treatment.

GHRP-2 vs. Ipamorelin

GHRP-2 and ipamorelin are synthetic GH secretagogues.

Both are associated with ghrelin receptor signaling.

However, their pharmacological profiles differ.

Ipamorelin was developed with an emphasis on selective GH-releasing activity in early experimental models.

GHRP-2 has demonstrated additional endocrine responses involving prolactin, ACTH and cortisol in human research.

These differences are relevant to receptor pharmacology and endocrine selectivity studies.

However, neither compound has established clinical efficacy for muscle growth, fat loss or longevity in healthy humans.

GHRP-2 vs. CJC-1295

GHRP-2 and CJC-1295 act through different receptor systems.

GHRP-2 primarily activates GHS-R1a.

CJC-1295 is a modified GHRH analogue that activates the GHRH receptor.

The compounds should not be treated as interchangeable.

Research involving combinations of GH secretagogues and GHRH analogues does not establish the safety or efficacy of unsupervised combined use.

Human Research on GHRP-2

Unlike many experimental peptides supported primarily by animal studies, GHRP-2 has been investigated in controlled human endocrine research.

These studies provide evidence of acute biological activity.

Growth Hormone Response

Human studies have demonstrated that GHRP-2 can stimulate GH secretion.

Prolactin, ACTH and Cortisol

Research has documented additional endocrine responses, although their magnitude varies by study and physiological conditions.

Appetite and Food Intake

Controlled studies have reported increases in hunger and food intake.

Endocrine Diagnostic Research

GHRP-2 has been investigated as a stimulus in pituitary function testing.

However, diagnostic performance depends on the clinical context, and results from one endocrine test cannot automatically be generalized to another.

Important Limitation

The presence of human endocrine research does not establish GHRP-2 as an approved general-purpose treatment for GH deficiency, muscle growth, weight management or aging.

Regulatory authorization must be assessed for the specific product, indication and jurisdiction.

Potential Safety Concerns

GHRP-2 influences endocrine pathways that regulate multiple physiological systems.

Important considerations include:

Changes in Growth Hormone Secretion

Excessive or inappropriate GH signaling may have adverse metabolic consequences.

Effects on Prolactin

Human studies have documented prolactin responses.

ACTH and Cortisol Responses

GHRP-2 can stimulate components of the HPA axis.

Appetite Changes

Increased hunger and food intake have been demonstrated experimentally.

Glucose Regulation

Changes in GH-associated signaling may influence glucose metabolism.

Long-Term Safety

The safety of repeated, unsupervised or prolonged exposure has not been adequately established.

Product Quality

Unverified research preparations may differ in identity, purity, peptide content and chemical form.

No laboratory research peptide should be assumed to be sterile, clinically suitable or safe for administration based solely on its product label.

GHRP-2 and Anti-Doping Regulations

GHRP-2 is specifically identified as a prohibited growth hormone-releasing peptide under the World Anti-Doping Agency (WADA) prohibited substance framework.

It is also known as pralmorelin in anti-doping documentation.

GHRP-2 is prohibited in sport both in and out of competition.

The presence of a substance in a research catalog does not exempt it from anti-doping regulations.

Researchers and organizations should also consider applicable national rules governing the handling and distribution of peptide hormones and related compounds.

Scientific Evidence and Research Limitations

GHRP-2 has a relatively well-characterized acute endocrine mechanism compared with many experimental peptides.

However, evidence quality differs substantially across proposed applications.

Established Research Findings

• GHRP-2 is a synthetic hexapeptide.

• It activates GHS-R1a-associated signaling.

• It stimulates acute GH secretion in humans.

• It can influence appetite and food intake.

• Human studies have reported prolactin, ACTH and cortisol responses.

• It has been investigated in endocrine diagnostic settings.

Important Limitations

• Long-term safety is insufficiently characterized.

• Clinical efficacy for muscle growth is not established.

• Clinical efficacy for fat loss is not established.

• Anti-aging and longevity claims are unsupported.

• Acute GH stimulation does not guarantee sustained IGF-1 elevation.

• Endocrine effects vary according to physiological conditions.

• Regulatory status varies by jurisdiction and product.

• Research-grade materials are not equivalent to authorized pharmaceutical preparations.

These limitations should be clearly communicated in scientific product descriptions.

Potential Research Applications

GHRP-2 may be relevant to appropriately controlled scientific investigations involving:

• Growth hormone secretion

• Ghrelin receptor pharmacology

• GHS-R1a signaling

• Hypothalamic–pituitary physiology

• GH–IGF-1 axis research

• G protein-coupled receptor biology

• Intracellular calcium signaling

• Pituitary somatotroph function

• Neuroendocrine feedback

• Prolactin-associated responses

• ACTH and cortisol signaling

• Appetite regulation

• Energy balance research

• Endocrine diagnostic methodology

• Peptide structure–activity relationships

• Synthetic peptide chemistry

• Growth hormone secretagogue selectivity

• Age-related endocrine physiology

These are scientific research areas rather than proven therapeutic benefits.

GHRP-2 Research Overview

Compound Name: Growth Hormone-Releasing Peptide-2

Alternative Name: Pralmorelin

Abbreviation: GHRP-2

Classification: Synthetic Growth Hormone Secretagogue

Peptide Length: 6 Amino Acid Residues

Sequence: H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂

Primary Receptor: GHS-R1a

Principal Research Pathway: Ghrelin Receptor Signaling

Primary Experimental Effect: Stimulation of GH Secretion

Additional Research Areas: Appetite / Prolactin / ACTH / Cortisol

Clinical Performance Benefits: Not established

Anti-Doping Status: Prohibited under WADA rules

Product Information

Product Name: GHRP-2

Full Name: Growth Hormone-Releasing Peptide-2

Alternative Name: Pralmorelin

Brand: ICAME Pharmacy

Product Category: Research Peptide

Research Classification: Synthetic Growth Hormone Secretagogue

Research Areas: GH Secretion / GHS-R1a Signaling / Neuroendocrine Physiology

Intended Use: Laboratory Research & Development Only

The exact identity and specifications of the supplied material must be verified through manufacturer documentation.

Relevant batch-specific information includes:

• Verified amino acid sequence

• Chemical form and counterion

• Molecular identity

• Analytical purity

• Peptide content

• Certificate of Analysis (COA)

• Batch/lot identification

• Validated storage conditions

No claim of pharmaceutical quality, sterility, human suitability or therapeutic efficacy should be made without appropriate supporting documentation and regulatory authorization.

Important Research Use Notice

FOR RESEARCH USE ONLY (RUO)

This ICAME Pharmacy product is intended exclusively for legitimate laboratory, analytical and scientific research purposes.

Not for human or veterinary use. Not for diagnostic, therapeutic, muscle-building, weight-loss, performance-enhancing, anti-aging or other clinical purposes. Not for direct administration to humans or animals.

GHRP-2 is a biologically active growth hormone secretagogue.

Human studies demonstrate acute endocrine activity, including stimulation of GH secretion and possible changes in prolactin, ACTH, cortisol and appetite.

However, long-term safety and clinical efficacy for performance, body composition and aging-related outcomes have not been established.

GHRP-2 is prohibited in sport under anti-doping regulations.

Information presented on this page is intended solely for scientific and educational purposes and does not constitute medical advice, prescribing information, dosage guidance or instructions for human use.

About ICAME Pharmacy

ICAME Pharmacy provides specialized research products for professional laboratory and scientific applications.

Our portfolio focuses on compounds relevant to peptide science, endocrinology, molecular biology, receptor signaling, experimental pharmacology and life sciences research.

We emphasize accurate product identification, responsible research use, scientific transparency and clear communication of evidence limitations.

For batch-specific analytical documentation and product inquiries, please contact ICAME Pharmacy.